ISLET Act
- Sponsor
- Rep. Norman, Ralph [R-SC-5]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Mar 19, 2026
Bottom line
The ISLET Act aims to streamline the regulatory pathway for human cadaveric islet transplantation by defining islets as organs, potentially increasing access to this treatment for diabetes.
What it actually does
This bill, the ISLET Act, amends the Public Health Service Act to classify human cadaveric islets as organs for transplantation, explicitly excluding them from regulation as drugs, biological products, or human cells, tissues, or cellular or tissue-based products (HCT/Ps). It mandates the Secretary of Health and Human Services to update relevant regulations within one year to reflect this reclassification.
Proponents argue
Proponents argue that classifying human cadaveric islets as organs will simplify the regulatory process, which is currently complex and burdensome under existing drug or biological product frameworks. This reclassification is expected to accelerate research, development, and availability of islet transplantation as a treatment for type 1 diabetes, potentially improving outcomes for patients who currently have limited options. They emphasize that islets function as a mini-organ, making organ classification appropriate and beneficial for patient access.
Opponents contend
Opponents might raise concerns that reclassifying islets as organs could reduce the level of regulatory scrutiny applied to their processing, quality control, and safety compared to the more rigorous standards for drugs or biological products. They might argue that while the intent is to increase access, a less stringent regulatory framework could potentially compromise patient safety or the efficacy of the transplants, especially given the complexities of cell-based therapies.
The bill is very short and straightforward, allowing for quick comprehension by any interested reader.
Section 1
Short Title
This section establishes the short title of the Act as the "Increase Support for Life-saving Endocrine Transplantation Act" or the "ISLET Act." This provides a common, easily referencable name for the legislation.
Supporters argue
A clear short title helps in public discourse and legislative tracking, making the bill's purpose more accessible.
Critics contend
No specific opposition is typically raised against short titles, as they are standard legislative practice.
Tradeoffs
None apparent.
Section 2(a)
Reclassification of Human Cadaveric Islets
This provision amends the Public Health Service Act to explicitly include "human cadaveric islets" in the definition of "organs" for transplantation purposes, alongside the pancreas. This reclassification is a fundamental change in how these cells are regulated.
Section 2(b)
Exclusion from Drug, Biologic, and HCT/P Definitions
This section explicitly states that human cadaveric islets are not to be considered a "drug," "biological product," or "human cells, tissues, or cellular or tissue-based products (HCT/Ps)" under existing federal law and regulations. This definitively removes them from these specific regulatory pathways.
Section 2(c)
Secretary to Update Regulations
This section mandates the Secretary of Health and Human Services to update regulations under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act within one year to implement the reclassification of human cadaveric islets as organs. It also requires a report to Congress on the progress of these updates within six months.